Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, it has been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
Company profile
Ticker
BAX
Exchange
Website
CEO
Jose Almeida
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Boston Scientific • Stryker • Becton, Dickinson And • 3M • Teleflex • Resmed • West Pharmaceutical Services • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
Corporate docs
Subsidiaries
Baxter Corporation • Baxter Healthcare Corporation • Baxter Pharmaceutical Solutions LLC • Baxter Sales and Distribution LLC • Cheetah Medical, Inc. • Gambro Renal Products, Inc. • Gambro UF Solutions, Inc. • Hill-Rom Holdings, Inc • Laboratorios Baxter S.A. • Synovis Life Technologies, Inc. ...
IRS number
360781620
BAX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
23 Mar 23
DEF 14A
Definitive proxy
23 Mar 23
8-K
Entry into a Material Definitive Agreement
13 Mar 23
8-K
Departure of Directors or Certain Officers
14 Feb 23
10-K
2022 FY
Annual report
9 Feb 23
8-K
Baxter Reports Fourth-quarter and Full-year 2022 Results
9 Feb 23
8-K
Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders
6 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Baxter Reports Third-quarter 2022 Results
27 Oct 22
8-K
Entry into a Material Definitive Agreement
30 Sep 22
Transcripts
BAX
Earnings call transcript
2022 Q4
9 Feb 23
BAX
Earnings call transcript
2022 Q3
27 Oct 22
BAX
Earnings call transcript
2022 Q2
28 Jul 22
BAX
Earnings call transcript
2022 Q1
28 Apr 22
BAX
Earnings call transcript
2021 Q4
17 Feb 22
BAX
Earnings call transcript
2021 Q3
28 Oct 21
BAX
Earnings call transcript
2021 Q2
29 Jul 21
BAX
Earnings call transcript
2021 Q1
29 Apr 21
BAX
Earnings call transcript
2020 Q4
4 Feb 21
BAX
Earnings call transcript
2020 Q3
29 Oct 20
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.72 bn | 1.72 bn | 1.72 bn | 1.72 bn | 1.72 bn | 1.72 bn |
| Cash burn (monthly) | (no burn) | 102.83 mm | (no burn) | 175.83 mm | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 283.39 mm | n/a | 484.57 mm | n/a | n/a |
| Cash remaining | n/a | 1.44 bn | n/a | 1.24 bn | n/a | n/a |
| Runway (months of cash) | n/a | 14.0 | n/a | 7.0 | n/a | n/a |
Institutional ownership, Q4 2022
86.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 976 |
| Opened positions | 109 |
| Closed positions | 117 |
| Increased positions | 309 |
| Reduced positions | 370 |
| 13F shares | Current |
|---|---|
| Total value | 22.19 tn |
| Total shares | 436.70 mm |
| Total puts | 1.64 mm |
| Total calls | 3.01 mm |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 50.52 mm | $2.58 tn |
| Vanguard | 49.71 mm | $2.53 tn |
| Wellington Management | 36.10 mm | $1.84 tn |
| MS Morgan Stanley | 29.61 mm | $1.51 tn |
| STT State Street | 21.50 mm | $1.10 tn |
| Generation Investment Management | 10.87 mm | $553.84 bn |
| Geode Capital Management | 8.80 mm | $446.29 bn |
| Nuveen Asset Management | 8.43 mm | $427.42 bn |
| MCQEF Macquarie | 7.79 mm | $397.01 bn |
| Norges Bank | 7.44 mm | $379.18 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Mar 23 | Reaz Rasul | Common Stock, $1 par value | Payment of exercise | Dispose F | No | No | 38.19 | 151 | 5.77 k | 26,765 |
| 20 Mar 23 | Heather Knight | Common Stock, $1 par value | Payment of exercise | Dispose F | No | No | 38.19 | 212 | 8.10 k | 53,110 |
| 20 Mar 23 | Stevens Brian | Common Stock, $1 par value | Payment of exercise | Dispose F | No | No | 38.19 | 161 | 6.15 k | 32,896 |
| 20 Mar 23 | Stroucken Albert P L | Common Stock, $1 par value | Sell | Dispose S | No | No | 37.52 | 3,930 | 147.45 k | 36,835 |
| 20 Mar 23 | Stroucken Albert P L | Common Stock, $1 par value | Option exercise | Acquire M | No | No | 36.93 | 3,930 | 145.13 k | 40,765 |
| 20 Mar 23 | Stroucken Albert P L | Stock Option Common Stock, $1 par value | Option exercise | Dispose M | No | No | 36.93 | 3,930 | 145.13 k | 0 |
| 3 Mar 23 | Heather Knight | Common Stock, $1 par value | Payment of exercise | Dispose F | No | No | 39.94 | 220 | 8.79 k | 53,322 |
News
'Thermo Fisher, Celltrion Vie For Baxter's Biopharma Unit -Sources' - Reuters News
21 Mar 23
Reuters Reported Thermo Fisher Scientific, South Korea's Celltrion, KKR And Carlyle Group Said To Be Competing To Acquire The Biopharma Solutions Business Of Baxter International
20 Mar 23
Stocks That Hit 52-Week Lows On Friday
10 Mar 23
Peering Into Baxter Intl's Recent Short Interest
9 Mar 23
Baxter Intl's Debt Overview
2 Mar 23
Press releases
Syringes Market Size To Hit US$ 27.45 Billion Growth By 2027, With a CAGR of 8.70%, Says IMARC Group
9 Mar 23
Baxter Declares Quarterly Dividend
14 Feb 23
Baxter to Host Fourth-Quarter 2022 Financial Results Conference Call for Investors
11 Jan 23
Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders
6 Jan 23